N-(4-chloro-phenyl)-N'-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N-methyl-[1,3,5]triazine-2,4-diamine | 1221273-99-9

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: N-(4-chloro-phenyl)-N'-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N-methyl-[1,3,5]triazine-2,4-diamine
• 英文别名: 2-N-(4-chlorophenyl)-4-N-[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]-2-N-methyl-1,3,5-triazine-2,4-diamine
• CAS: 1221273-99-9
• 化学式: C₂₁H₂₀ClN₇O
• 分子量: 421.889
• InChiKey: AEVSFVMTLNSCCW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  81
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (4-chloro-[1,3,5]triazin-2-yl)-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-amine 、 4-氯-N-甲基苯胺 以 乙酸乙酯 为溶剂， 以gave the title compound as a colorless solid in 23% yield的产率得到N-(4-chloro-phenyl)-N'-[3-methoxy-4-(4-methyl-imidazol-1-yl)-phenyl]-N-methyl-[1,3,5]triazine-2,4-diamine
  参考文献：
  名称：

  MODULATORS FOR AMYLOID BETA

  摘要：

  本发明涉及具有以下式的化合物，其中R1、R2、R3、R4和Ar如规范和要求中所定义的，或者是这些化合物的药物活性酸盐加合物。式I的化合物是淀粉样β的调节剂，可能对治疗或预防与脑中β-淀粉样物沉积相关的疾病，特别是阿尔茨海默病以及其他疾病，如脑淀粉样血管病、遗传性脑出血伴淀粉样变性、荷兰型（HCHWA-D）、多发性梗死性痴呆、拳击性痴呆和唐氏综合症具有用处。

  公开号：

  US20120190682A1

文献信息

• [EN] MODULATORS FOR AMYLOID BETA<br/>[FR] MODULATEURS POUR L'AMYLOÏDE BÊTA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010040661A1

  公开（公告）日：2010-04-15

  The invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl or is lower alkyl substituted by hydroxy; R2 is hydrogen, lower alkoxy or lower alkyl; R3/R4 are independently from each other hydrogen, halogen, lower alkyl, C(O)O-lower alkyl, OR', NR''R"', lower alkyl substituted by halogen or hydroxy, or is phenyl or benzyl, optionally substituted by one or two halogen atoms; R' is lower alkyl, or is phenyl, benzyl or pyridinyl, which rings are optionally substituted by one or more halogen, lower alkyl or lower alkyl substituted by fluoro; R'' is hydrogen or lower alkyl; R'" is lower alkyl, lower alkyl substituted by one or two hydroxy groups, CH(CH2OH)-phenyl, or is -(CH2)2O-lower alkyl, or is phenyl substituted by halogen, or R'' and R''' form together with the N-atom to which they are attached a heterocyclic ring, optionally substituted by one or more lower alkyl, CH2C(O)O-lower alkyl, or by CH2C(O)OH; Ar is a fϊve-membered heteroaryl group; or to pharmaceutically active acid addition salts. It has been found that the present compounds of formula (I) are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

  本发明涉及式(I)的化合物，其中R1为氢、低烷基或被羟基取代的低烷基；R2为氢、低烷氧基或低烷基；R3/R4分别独立地为氢、卤素、低烷基、C(O)O-低烷基、OR'、NR''R'''、被卤素或羟基取代的低烷基，或为苯基或苄基，可选择性地被一个或两个卤素原子取代；R'为低烷基，或为苯基、苄基或吡啶基，这些环可选择性地被一个或多个卤素、低烷基或被氟取代的低烷基取代；R''为氢或低烷基；R'''为低烷基，被一个或两个羟基取代的低烷基，CH( OH)-苯基，或为-(CH2)2O-低烷基，或为被卤素取代的苯基，或R''和R'''与它们连接的N原子一起形成一个杂环，可选择性地被一个或多个低烷基、 C(O)O-低烷基或 C(O)OH取代；Ar为五元杂芳基；或为药用活性酸盐。已发现，式(I)的这些化合物是淀粉样β的调节剂，因此它们可能对治疗或预防与β-淀粉在大脑中沉积相关的疾病有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病、家族性脑出血伴淀粉样变性、荷兰型多梗塞性痴呆、拳击性痴呆和唐氏综合征。
• Modulators for amyloid beta
  申请人：Goetschi Erwin

  公开号：US08389717B2

  公开（公告）日：2013-03-05

  The invention relates to compounds of formula wherein R1, R2, R3, R4, and Ar are as defined in the specification and claims, or to pharmaceutically active acid addition salts of such compounds. Compounds of formula I are modulators for amyloid beta and may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

  本发明涉及式I的化合物，其中R1、R2、R3、R4和Ar如规范和权利要求中所定义，或其药物活性酸盐。式I的化合物是淀粉样β的调节剂，可能对与β-淀粉样物在脑中沉积相关的疾病的治疗或预防有用，特别是阿尔茨海默病，以及其他疾病，如脑淀粉样血管病、遗传性淀粉样物溢血性脑病，荷兰型（HCHWA-D）、多发性梗死性痴呆、拳击性痴呆和唐氏综合症。
• US8389717B2
  申请人：——

  公开号：US8389717B2

  公开（公告）日：2013-03-05